Hanmi Pharm. Co., Ltd. (KRX:128940)

South Korea flag South Korea · Delayed Price · Currency is KRW
423,000
-7,000 (-1.63%)
Last updated: Dec 5, 2025, 1:28 PM KST
54.95%
Market Cap 5.40T
Revenue (ttm) 1.47T
Net Income (ttm) 116.48B
Shares Out 12.68M
EPS (ttm) 9,186.54
PE Ratio 46.37
Forward PE 31.42
Dividend 1,250.00 (0.29%)
Ex-Dividend Date n/a
Volume 65,817
Average Volume 123,783
Open 427,500
Previous Close 430,000
Day's Range 415,000 - 429,000
52-Week Range 214,500 - 494,000
Beta 0.48
RSI 45.56
Earnings Date Feb 13, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha... [Read more]

Sector Healthcare
Founded 1973
Employees 2,400
Stock Exchange Korea Stock Exchange
Ticker Symbol 128940
Full Company Profile

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.

Financial Statements